Short answer
Emergent BioSolutions Inc. (EBS) filed an 8-K current report with the SEC on September 14, 2026 reporting Item 7.01 (Regulation FD Disclosure). CEO Joseph C. Papa scheduled to present at H.C. Wainwright’s 28th Annual Global Investment Conference on September 14, 2026.
Emergent BioSolutions Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- CEO Joseph C. Papa scheduled to present at H.C. Wainwright’s 28th Annual Global Investment Conference on September 14, 2026
- Investor presentation slides furnished as Exhibit 99.1, likely providing updated company messaging and outlook
- Conference appearance creates near-term opportunity for management commentary relevant to investors
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Emergent BioSolutions Inc. 8-K filings
Get the next EBS 8-K as it lands
Follow EBS for push alerts, or ask the research agent what this filing means.